斑秃免疫学机制研究进展
Advances in the Research of the Immunological Mechanisms of Alopecia Areata
DOI: 10.12677/acm.2024.1441049, PDF,    科研立项经费支持
作者: 王 敏:大理大学临床医学院,云南 大理;王敏华*:大理大学第一附属医院皮肤科,云南 大理
关键词: 斑秃自身免疫免疫学发病机制Alopecia Areata Autoimmunity Immunology Pathogenesis
摘要: 斑秃是一种突发的炎症性、非瘢痕性的脱发性疾病,临床表现为斑片状脱发、全部头发脱落、全身毛发的脱落。本病具有自限性,但易复发,当前治疗效果的数据有限。目前斑秃的发病机制尚未完全了解,但越来越多的证据证明斑秃是一种免疫介导的疾病。近年来,随着不断的深入研究及靶向精准治疗的发展,参与斑秃的免疫学机制也随之进展。本文就斑秃免疫学机制及研究进展进行综述。
Abstract: Alopecia areata is a sudden-onset, inflammatory, non-scarring hair loss disease, clinically manifested as patchy hair loss, complete loss of hair on the scalp, and loss of body hair. The disease is self-limiting but prone to recurrence, and data on the current treatment efficacy are limited. The pathogenesis of alopecia areata is not fully understood, but increasing evidence suggests that it is an immune-mediated disease. In recent years, with continuous in-depth research and the development of targeted precision therapy, the understanding of the immunological mechanisms involved in alopecia areata has progressed. This article provides a comprehensive review of the immunological mechanisms and research progress in alopecia areata.
文章引用:王敏, 王敏华. 斑秃免疫学机制研究进展[J]. 临床医学进展, 2024, 14(4): 489-496. https://doi.org/10.12677/acm.2024.1441049

参考文献

[1] Lee, H.H., Gwillim, E., Patel, K.R., et al. (2020) Epidemiology of Alopecia Areata, Ophiasis, Totalis, and Universalis: A Systematic Review and Meta-Analysis. Journal of the American Academy of Dermatology, 82, 675-682. [Google Scholar] [CrossRef] [PubMed]
[2] Jang, H., Park, S., Kim, M.S., et al. (2023) Global, Regional and National Burden of Alopecia Areata and Its Associated Diseases, 1990-2019: A Systematic Analysis of the Global Burden of Disease Study 2019. European Journal of Clinical Investigation, 53, e13958. [Google Scholar] [CrossRef] [PubMed]
[3] Simakou, T., Butcher, J.P., Reid, S., et al. (2019) Alopecia Areata: A Multifactorial Autoimmune Condition. Journal of Autoimmunity, 98, 74-85. [Google Scholar] [CrossRef] [PubMed]
[4] Bertolini, M., McElwee, K., Gilhar, A., et al. (2020) Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata. Experimental Dermatology, 29, 703-725. [Google Scholar] [CrossRef] [PubMed]
[5] Pratt, C.H., King, L.E., Messenger, A.G., et al. (2017) Alopecia Areata. Nature Reviews Disease Primers, 3, Article No. 17011. [Google Scholar] [CrossRef] [PubMed]
[6] Paus, R., Nickoloff, B. and Ito, T. (2005) A  ‘Hairy’ Privilege. Trends in Immunology, 26, 32-40. [Google Scholar] [CrossRef] [PubMed]
[7] Żeberkiewicz, M., Rudnicka, L. and Malejczyk, J. (2020) Immunology of Alopecia Areata. Central European Journal of Immunology, 45, 325-333. [Google Scholar] [CrossRef] [PubMed]
[8] Zhou, C., Li, X., Wang, C., et al. (2021) Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management. Clinical Reviews in Allergy & Immunology, 61, 403-423. [Google Scholar] [CrossRef] [PubMed]
[9] Dobreva, A., Paus, R. and Cogan, N.G. (2018) Analysing the Dynamics of a Model for Alopecia Areata as an Autoimmune Disorder of Hair Follicle Cycling. Mathematical Medicine and Biology : A Journal of the IMA, 35, 387-407. [Google Scholar] [CrossRef] [PubMed]
[10] Paus, R., Ito, N., Takigawa, M., et al. (2003) The Hair Follicle and Immune Privilege. Journal of Investigative Dermatology Symposium Proceedings, 8, 188-194. [Google Scholar] [CrossRef] [PubMed]
[11] Anzai, A., Wang, E.H.C., Lee, E.Y., et al.(2019) Pathomechanisms of Immune-Mediated Alopecia. International Immunology, 31, 439-447. [Google Scholar] [CrossRef] [PubMed]
[12] Xing, L., Dai, Z., Jabbari, A., et al. (2014) Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition. Nature Medicine, 20, 1043-1049. [Google Scholar] [CrossRef] [PubMed]
[13] Mcelwee, K.J., Freyschmidt-Paul, P. and VitaItacolonna, M. (2005) Transfer of CD8 Þ Cells Induces Localized Hair Loss Whereas CD4 Þ /CD25À Cells Promote Systemic Alopecia Areata and CD4 Þ /CD25 Þ Cells Blockade Disease Onset in the C3H/HeJ Mouse Model. The Journal of Investigative Dermatology, 124, 947-957. [Google Scholar] [CrossRef
[14] Eagle, R.A., Traherne, J.A., Hair, J.R., et al. (2009) ULBP6/RAET1L Is an Additional Human NKG2D Ligand. European Journal of Immunology, 39, 3207-3216. [Google Scholar] [CrossRef] [PubMed]
[15] Petukhova, L., Duvic, M., Hordinsky, M., et al. (2010) Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity. Nature, 466, 113-117. [Google Scholar] [CrossRef] [PubMed]
[16] Hashimoto, K., Yamada, Y., Fujikawa, M., et al. (2021) Altered T Cell Subpopulations and Serum Anti-TYRP2 and Tyrosinase Antibodies in the Acute and Chronic Phase of Alopecia Areata in the C3H/HeJ Mouse Model. Journal of Dermatological Science, 104, 21-29. [Google Scholar] [CrossRef] [PubMed]
[17] Zhang, X., Zhao, Y., Ye, Y., et al. (2015) Lesional Infiltration of Mast Cells, Langerhans Cells, T Cells and Local Cytokine Profiles in Alopecia Areata. Archives of Dermatological Research, 2015, 307, 319-331. [Google Scholar] [CrossRef] [PubMed]
[18] Passeron, T., King, B., Seneschal, J., et al. (2023) Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions. Frontiers in Immunology, 14, Article 1243556. [Google Scholar] [CrossRef] [PubMed]
[19] Kasumagić-Halilovic, E., Cavaljuga, S., Ovcina-Kurtovic, N., et al. (2018) Serum Levels of Interleukin-2 in Patients with Alopecia Areata: Relationship with Clinical Type and Duration of the Disease. Skin Appendage Disorders, 4, 286-290. [Google Scholar] [CrossRef] [PubMed]
[20] Omar, S.I., Hamza, A.M., Eldabah, N., et al. (2021) IFN-α and TNF-α Serum Levels and Their Association with Disease Severity in Egyptian Children and Adults with Alopecia Areata. International Journal of Dermatology, 60, 1397-1404. [Google Scholar] [CrossRef] [PubMed]
[21] Barahmani, N., Lopez, A., Babu, D., et al. (2010) Serum T Helper 1 Cytokine Levels Are Greater in Patients with Alopecia Areata Regardless of Severity or Atopy. Clinical and Experimental Dermatology, 35, 409-416. [Google Scholar] [CrossRef] [PubMed]
[22] Waśkiel-Burnat, A., Osińska, M., Salińska, A., et al. (2021) The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications. Cells, 10, Article 3397. [Google Scholar] [CrossRef] [PubMed]
[23] Sato-Kawamura, M., Aiba, S. and Tagami, H. (2003) Strong Expression of CD40, CD54 and HLA-DR Antigen and Lack of Evidence for Direct Cellular Cytotoxicity Are Unique Immunohistopathological Features in Alopecia Areata. Archives of Dermatological Research, 294, 536-543. [Google Scholar] [CrossRef] [PubMed]
[24] Zaaroura, H., Gilding, A.J. and Sibbald, C. (2023) Biomarkers in Alopecia Areata: A Systematic Review and Meta-Analysis. Autoimmunity Reviews, 22, Article ID: 103339. [Google Scholar] [CrossRef] [PubMed]
[25] Czarnowicki, T., He, H.Y., Wen, H.C., et al. (2018) Alopecia Areata Is Characterized by Expansion of Circulating Th2/Tc2/Th22, within the Skin-Homing and Systemic T-Cell Populations. Allergy, 73, 713-723. [Google Scholar] [CrossRef] [PubMed]
[26] Mohan, G.C. and Silverberg, J.I. (2015) Association of Vitiligo and Alopecia Areata with Atopic Dermatitis: A Systematic Review and Meta-Analysis. JAMA Dermatology, 151, 522-528. [Google Scholar] [CrossRef] [PubMed]
[27] Yan, X., Tayier, M., Cheang, S.T., et al. (2023) Hair Repigmentation and Regrowth in a Dupilumab-Treated Paediatric Patient with Alopecia Areata and Atopic Dermatitis: A Case Report. Therapeutic Advances in Chronic Disease, 14. [Google Scholar] [CrossRef] [PubMed]
[28] Guttman-Yassky, E., Renert-Yuval, Y., Bares, J., et al. (2022) Phase 2a Randomized Clinical Trial of Dupilumab (Anti-IL-4Rα) for Alopecia Areata Patients. Allergy, 77, 897-906. [Google Scholar] [CrossRef] [PubMed]
[29] Ito, T., Kageyama, R., Nakazawa, S. and Honda, T. (2020) Understanding the Significance of Cytokines and Chemokines in the Pathogenesis of Alopecia Areata. Experimental Dermatology, 29, 726-732. [Google Scholar] [CrossRef] [PubMed]
[30] Wu, B., Zhang, S., Guo, Z., et al. (2021) The TGF-β Superfamily Cytokine Activin-A Is Induced during Autoimmune Neuroinflammation and Drives Pathogenic Th17 Cell Differentiation. Immunity, 54, 308-323.E6. [Google Scholar] [CrossRef] [PubMed]
[31] Guttman-Yassky, E., Nia, J.K., Hashim, P.W., et al. (2018) Efficacy and Safety of Secukinumab Treatment in Adults with Extensive Alopecia Areata. Archives of Dermatological Research, 310, 607-614. [Google Scholar] [CrossRef] [PubMed]
[32] Słowińska, M., Kardynal, A., Warszawik, O., et al. (2010) Alopecia Areata Developing Paralell to Improvement of Psoriasis during Ustekinumab Therapy. Journal of Dermatological Case Reports, 4, 15-17. [Google Scholar] [CrossRef] [PubMed]
[33] Wing, K., Onishi, Y., Prieto-Martin, P., et al. (2008) CTLA-4 Control over Foxp3 Regulatory T Cell Function. Science, 322, 271-275. [Google Scholar] [CrossRef] [PubMed]
[34] Speiser, J.J., Mondo, D., Mehta, V., et al. (2019) Regulatory T-Cells in Alopecia Areata. Journal of Cutaneous Pathology, 46, 653-658. [Google Scholar] [CrossRef] [PubMed]
[35] Zheng, Y. and Rudensky. A.Y. (2007) Foxp3 in Control of the Regulatory T Cell Lineage. Nature Immunology, 8, 457-462. [Google Scholar] [CrossRef] [PubMed]
[36] Loh, S.H., Moon, H.N., Lew, B.L., et al. (2018) Role of T Helper 17 Cells and T Regulatory Cells in Alopecia Areata: Comparison of Lesion and Serum Cytokine between Controls and Patients. Journal of the European Academy of Dermatology and Venereology, 32, 1028-1033. [Google Scholar] [CrossRef] [PubMed]
[37] Rossi, A., Cantisani, C., Carlesimo, M., et al. (2012) Serum Concentrations of IL-2, IL-6, IL-12 and TNF-α in Patients with Alopecia Areata. International Journal of Immunopathology and Pharmacology, 25, 781-788. [Google Scholar] [CrossRef] [PubMed]
[38] Kubo, R., Muramatsu, S., Sagawa, Y., et al. (2017) Activated Regulatory T Cells Are Increased in Patients with Alopecia Areata for Suppressing Disease Acitivity. Journal of Dermatological Science, 86, E27-E28. [Google Scholar] [CrossRef
[39] Jalili, R.B., Kilani, R.T., Li, Y., et al. (2023) The Potential of Regulatory T Cell-Based Therapies for Alopecia Areata. Frontiers in Immunology, 14, Article 1111547. [Google Scholar] [CrossRef] [PubMed]
[40] Ito, T., Ito, N., Saatoff, M., et al. (2008) Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack. The Journal of Investigative Dermatology, 128, 1196-1206. [Google Scholar] [CrossRef] [PubMed]
[41] Shi, F.D. and Van Kaer, L. (2006) Reciprocal Regulation between Natural Killer Cells and Autoreactive T Cells. Nature Reviews Immunology, 6, 751-760. [Google Scholar] [CrossRef] [PubMed]
[42] Abou Rahal., J., Kurban, M., Kibbi, A.G. and Abbas, O. (2016) Plasmacytoid Dendritic Cells in Alopecia Areata: Missing Link? Journal of the European Academy of Dermatology and Venereology, 30, 119-123. [Google Scholar] [CrossRef] [PubMed]
[43] Ito, T., Suzuki, T., Sakabe, J.I., et al. (2020) Plasmacytoid Dendritic Cells as a Possible Key Player to Initiate Alopecia Areata in the C3H/HeJ Mouse. Allergology International, 69, 121-131. [Google Scholar] [CrossRef] [PubMed]
[44] Dias De Oliveira, N.F., Santi, C.G., Maruta, C.W., et al. (2021) Plasmacytoid Dendritic Cells in Dermatology. Anais Brasileiros de Dermatologia, 96, 76-81. [Google Scholar] [CrossRef] [PubMed]
[45] Tomaszewska, K., Kozłowska, M., Kaszuba, A., et al. (2020) Increased Serum Levels of IFN-γ, IL-1β, and IL-6 in Patients with Alopecia Areata and Nonsegmental Vitiligo. Oxidative Medicine and Cellular Longevity, 2020, Article ID: 5693572. [Google Scholar] [CrossRef] [PubMed]
[46] Tabara, K., Kozłowska, M., Jędrowiak, A., et al. (2019) Serum Concentrations of Selected Proinflammatory Cytokines in Children with Alopecia Areata. Postepy Dermatologii i Alergologii, 36, 63-69. [Google Scholar] [CrossRef] [PubMed]
[47] Ma, X., Chen, S., Jin, W. and Gao, Y. (2017) Th1/Th2 PB Balance and CD200 Expression of Patients with Active Severe Alopecia Areata. Experimental and Therapeutic Medicine, 13, 2883-2887. [Google Scholar] [CrossRef] [PubMed]
[48] Agamia, N., Apalla, Z., El Achy, S., et al. (2020) Interferon-γ Serum Level and Immunohistochemical Expression of CD8 Cells in Tissue Biopsies in Patients with Alopecia Areata in Correlation with Trichoscopic Findings. Dermatologic Therapy, 33, e13718. [Google Scholar] [CrossRef] [PubMed]
[49] Monteleone, G., Pallone, F. and Macdonald, T.T. (2009) Interleukin-21 as a New Therapeutic Target for Immune-Me-diated Diseases. Trends in Pharmacological Sciences, 30, 441-447. [Google Scholar] [CrossRef] [PubMed]
[50] Dai, Z., Xing, L., Cerise, J., et al. (2016) CXCR3 Blockade Inhibits T Cell Migration Into the Skin and Prevents Development of Alopecia Areata. Journal of Immunology, 197, 1089-1099. [Google Scholar] [CrossRef] [PubMed]
[51] Gilhar, A., Laufer-Britva, R., Keren, A. and Paus, R. (2019) Frontiers in Alopecia Areata Pathobiology Research. The Journal of Allergy and Clinical Immunology, 144, 1478-1489. [Google Scholar] [CrossRef] [PubMed]
[52] Kamil, Z.A., Abdullah, G.A. and Zalzala, H.H. (2023) Interleukin-15 and Tumor Necrosis Factor-α in Iraqi Patients with Alopecia Areata. Dermatology Research and Practice, 2023, Article ID: 5109772. [Google Scholar] [CrossRef] [PubMed]
[53] Waldmann, T.A. (2004) Targeting the Interleukin-15/Interleukin-15 Receptor System in Inflammatory Autoimmune Diseases. Arthritis Research & Therapy, 6, Article No. 174. [Google Scholar] [CrossRef] [PubMed]
[54] El Aziz Ragab, M.A., Hassan, E.M., El Niely, D.A.E.M., et al.(2020) Serum Level of Interleukin-15 in Active Alopecia Areata Patients and Its Relation to Age, Sex, and Disease Severity. Postepy Dermatologii i Alergologii, 37, 904-908. [Google Scholar] [CrossRef] [PubMed]
[55] Waldmann, T.A. (2013) The Biology of IL-15: Implications for Cancer Therapy and the Treatment of Autoimmune Disorders. The Journal of Investigative Dermatology Symposium Proceedings, 16, S28-S30. [Google Scholar] [CrossRef] [PubMed]
[56] O’Shea, J.J., Schwartz, D.M., Villarino, A.V., et al. (2015) The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention. Annual Review of Medicine, 66, 311-328. [Google Scholar] [CrossRef] [PubMed]
[57] O’Shea, J.J. and Plenge, R. (2012) JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease. Immunity, 36, 542-550. [Google Scholar] [CrossRef] [PubMed]
[58] Hogan, S., Wang, S., Ibrahim, O., et al. (2019) Long-Term Treatment with Tofacitinib in Severe Alopecia Areata: An Update. The Journal of Clinical and Aesthetic Dermatology, 12, 12-14.
[59] Almutairi, N., Nour, T.M. and Hussain, N.H. (2019) Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study. Dermatology, 235, 130-136. [Google Scholar] [CrossRef] [PubMed]
[60] King, B., Ohyama, M., Kwon, O., et al. (2022) Two Phase 3 Trials of Baricitinib for Alopecia Areata. The New England Journal of Medicine, 386, 1687-1699. [Google Scholar] [CrossRef
[61] Muddebihal, A, Khurana, A. and Sardana, K. (2023) JAK Inhibitors in Dermatology: The Road Travelled and Path Ahead, a Narrative Review. Expert Review of Clinical Pharmacology, 16, 279-295. [Google Scholar] [CrossRef] [PubMed]
[62] Sechi, A., Song, J., Dell’Antonia, M., et al. (2023) Adverse Events in Patients Treated with Jak-Inhibitors for Alopecia Areata: A Systematic Review. Journal of the European Academy of Dermatology and Venereology, 37, 1535-1546. [Google Scholar] [CrossRef] [PubMed]